Table 1 Statement categorization
Section 1: Patient population | Section 2: Dosage, management & adverse events | Section 3: Functional recovery domains & assessment |
|---|---|---|
• Generic LAI use • Potential exclusions • Appropriateness for FEP and EP patients | • Adverse event management • Psychotic episodes on LAI • Loss of efficacy • LAI dosing & intervals for FEP and EP patients | • Long-term treatment goals • LAI links to functional recovery • Functional recovery domain • Functional recovery assessment • Achieved functional recovery |